Alpha Lipoic Acid injection vials recalled for sterility assurance defect
Olympia Compounding Pharmacy is recalling 3,286 vials of Alpha Lipoic Acid 25 mg/mL due to inability to assure sterility. Patients should contact their healthcare provider to verify their medication and discuss alternatives.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of a pharmaceutical product with a confirmed manufacturing defect affecting sterility assurance. This meets the rubric criterion for risk-of-harm products (injectable medication) where injury has not yet been reported; the rule limiting theoretical hazards to Score 3 maximum applies here.
Plain-English summary
Olympia Compounding Pharmacy is recalling 3,286 vials of Alpha Lipoic Acid 25 mg/mL (NDC 73198-0076-30), a prescription injectable medication, because the manufacturer cannot assure the product meets required sterility standards. The vials were distributed nationwide throughout the United States, Puerto Rico, and the U.S. Virgin Islands under lot numbers L24C06, L24B06, and B41023-22.
The recall stems from a manufacturing defect in the compounding process that compromises the assurance of sterility. Although no illnesses or infections have been reported to date, non-sterile injectable medications pose a risk of serious infection to patients.
Patients who have received this medication should contact their healthcare provider to determine whether their dose is from an affected lot. Healthcare providers should review patient records to identify anyone who may have received the recalled vials and should provide affected patients with alternative medication.
The recalled product
- Product
- Alpha Lipoic Acid 25 mg/mL, Multi-Dose 30 mL vial, Rx Only, Olympia Pharmaceuticals, 6700 Conroy Rd., Ste. 155 Orlando, FL 32835, NDC 73198-0076-30
- Manufacturer
- Olympia Compounding Pharmacy dba Olympia Pharmacy
- Category
- Drug — Injectable Medication
- Hazard
- sterility-failure
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lots: L24C06
- L24B06 BUD: 6/6/2022
- B41023-22 BUD: 8/23/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27